Director of Clinical Research

A Director of Clinical Research owns the scientific foundation of a clinical development program. They are accountable for whether the questions asked in the trials are the right questions, whether the design can answer them, and whether the resulting data supports the regulatory story needed for approval.

Protocol development is the most consequential upstream activity in clinical research. A trial designed with endpoints that can't detect the effect of interest, eligibility criteria that exclude the patients most likely to respond, or assessments that are impractical in a real clinical setting will fail regardless of how well it's executed. The Director leads the cross-functional team through these design decisions, integrates input from biostatistics, regulatory affairs, and medical affairs, and takes accountability for the scientific rationale in the final document.

FDA and EMA interactions are where the Director's external visibility matters most. A Type B pre-Phase III meeting is an opportunity to get agency alignment on a proposed pivotal design before investing $50M in executing it. The Director prepares and reviews the briefing document, leads or participates in the meeting, and ensures the agency's feedback is correctly incorporated into the program plan. Misinterpreting an FDA comment in this context can cost years.

Safety oversight is a continuous responsibility. As patients enroll and take the investigational product, adverse event data accumulates. The Director reviews SAE narratives for clinical significance, interacts with the DSMB, and decides whether emerging safety signals warrant protocol amendments, IND safety reports, or program pauses. These decisions require both medical knowledge and regulatory judgment — the combination that makes a Director-level role more than a managerial position.

Education:

• MD or MD/PhD for roles with primary medical monitoring and safety oversight responsibilities
• PhD in pharmacology, oncology, immunology, or a related biomedical science for scientific leadership roles without direct patient care requirements
• PharmD for roles at the intersection of clinical pharmacology and development strategy
• Board certification adds credibility in therapeutic areas where clinical practice informs development decisions

Experience:

• 12–18 years in clinical research, including 5+ years at a senior level with program leadership responsibility
• At least one IND held and advanced through multiple Phase transitions
• Direct FDA interaction experience: led or co-led at least one Type B or C meeting
• Cross-functional development team leadership: experience integrating clinical operations, biostatistics, regulatory, and commercial perspectives
• CRO and academic collaboration management at the Principal Investigator or sponsor representative level

Scientific and regulatory knowledge:

• Therapeutic area scientific depth: literature currency and mechanistic understanding of the relevant disease biology
• ICH guideline suite: E6(R3), E3, E8, E9(R1), E10, M7, M11 as relevant to program type
• FDA Guidance documents for the relevant therapeutic area and product type
• Clinical pharmacology: PK/PD principles for dose selection and proof-of-concept interpretation
• Adaptive trial designs: platform trials, Bayesian endpoints, seamless Phase II/III designs

Leadership and communication:

• Scientific writing at the regulatory document level — not polished prose, but precise, defensible scientific language
• Executive and board communication: translating clinical program status into business-language risk assessments
• Scientific talent development: mentoring clinical scientists and building research capability

Director of Clinical Research roles sit in one of the most active hiring markets in all of life sciences. The combination of a large global clinical trial pipeline, increasing regulatory complexity, and a limited supply of doctoral-level scientists with both deep scientific expertise and regulatory experience creates persistent demand at this level.

Oncology continues to dominate hiring volume — more Phase I through III oncology trials are active than in any other therapeutic area, and the complexity of immuno-oncology, cellular therapies, and combination regimens requires senior scientific leadership at every program. Rare disease and gene therapy are growing sectors where small patient populations and novel regulatory frameworks require Directors with experience in surrogate endpoint strategy and adaptive design.

The biotech sector is the dominant employer at this level. Major pharma companies maintain large clinical research staffs, but biotech has generated more new Director-level positions over the past decade as growth-stage companies scale from proof-of-concept toward pivotal programs. The compensation packages at pre-commercial biotechs include equity stakes that can be highly valuable at IPO or acquisition — which attracts talent despite the higher organizational risk compared to large pharma.

AI tools are reshaping the work environment but not the underlying demand for scientific judgment. Protocol design assistance, regulatory document drafting, and literature synthesis all benefit from AI augmentation, allowing Directors and their teams to work faster. But FDA-facing scientific decisions, DSMB management, and safety oversight remain deeply human responsibilities that regulators hold named individuals accountable for.

For Directors with successful pivotal trials and NDA/BLA submissions in their track record, the market is favorable regardless of economic cycle. Companies entering their most important clinical stage — Phase III pivotal — are willing to pay significantly to secure leadership with demonstrated success at that inflection point.

Dear Hiring Manager,

I'm applying for the Director of Clinical Research position at [Company]. I hold an MD from [Medical School] and completed a fellowship in [specialty] at [Institution], and I've spent the past nine years in clinical development — the last four as Senior Medical Director at [Company] leading the Phase II and early Phase III program for [compound description] in [indication].

The program I'm most proud of shaped my thinking about clinical development decisions. We were designing a Phase IIb study, and the initial protocol proposed a primary endpoint that our biostatistics team estimated would require 450 patients per arm to power adequately. I pushed for a pre-Phase IIb meeting with FDA to discuss whether a PK/PD-based surrogate would be acceptable as a primary endpoint with the full clinical outcome as a secondary. FDA was receptive; the revised design required 180 patients per arm, cut the timeline by 14 months, and generated data that was fully informative for Phase III design.

I have direct experience managing two DSMBs — one on a cardiovascular outcomes trial and one on a rare disease pediatric study — and I've led both Type B and Type C meetings with FDA across three different programs. I'm comfortable with the full regulatory interaction cycle.

What draws me to [Company]'s program is the mechanistic rationale for [compound/approach] in [indication] — I've followed the published literature closely and believe the Phase II signal warrants the Phase III investment you're planning, for reasons I'd welcome the chance to discuss in detail.

[Your Name]